DUSA Pharmaceuticals Report issue

Contributed to NME For profit Phase 4
Founded: Wilmington MA United States (1991)
Status: Acquired by Sun Pharmaceuticals (2012)

Organization Overview

First Clinical Trial
2007
NCT00706433
First Marketed Drug
1999
aminolevulinic acid (levulan)
First NDA Approval
1999
aminolevulinic acid (levulan)
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

DUSA | DUSA Pharmaceuticals, Inc.

Active Ingredients

Marketed Drugs (1)

aminolevulinic acid (levulan) (1999 NDA)

Drugs in Phase 4 Trials (1)

aminolevulinic acid (levulan) (17 trials)

Drugs in Other Trials (2)

amino acids (Freamine) (1 trial)

cetirizine (zyrtec) (1 trial)

Indications

Approved Indications


 

Condylomata Acuminata

Glioma

Keratosis, Actinic

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Brain Neoplasms (Phase 2)

Cheilitis (Phase 4)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Rosacea (Phase 4)

Skin Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 3